Deafness Genes in Israel: Implications for Diagnostics in the Clinic

ZIPPORA BROWNSTEIN AND KAREN B. AVRAHAM

Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, 69978 Israel

ABSTRACT: The identification of the molecular basis of deafness in the last decade has made a remarkable impact on genetic counseling and diagnostics for the hearing impaired population. Since the discovery of the most prevalent form of deafness associated with mutations in the GJB2 (connexin 26) gene, many other genes have been found worldwide, with a subset of these, including unique mutations, in Israel. Here, we review the current status of deafness genes in Israel and report one known mutation in a syndromic form of deafness, Usher syndrome, described in the Jewish Israeli population for the first time. In the future, the identification of specific mutations may be relevant for specific types of treatment. (Pediatr Res 66: 128–134, 2009)

Hereditary Hearing Loss

Patients with hearing loss (HL) and parents of hearing impaired children often wish to discover the cause of this most common sensory characteristic, one in which both medical geneticists and otolaryngologists are involved. The presence of a particular mutation may aid in making decisions regarding treatments and interventions, as well as prognosis for the future. Nonsyndromic deafness affects approximately 1 in 1000 newborns and 4% of people aged younger than 45 y (1). This number rises dramatically in regions where consanguinity is an acceptable social custom and is encouraged (2,3). Progressive HL affects an even greater proportion of the population. Approximately one quarter of persons develop HL by the age of 65 (1) and ~50% of persons by age 80 (4). HL is estimated to be inherited or has a genetic basis in approximately 60% of cases (5). Genetic HL includes ~30% syndromic HL (SHL), associated with other clinical findings such as blindness and neurologic defects, and 70% non-SHL (NSHL), where HL is an isolated characteristic (6).

Because in diverse populations different genes are involved, genetic evaluation of each population should be based on an empirical study of that population. In this article, we review the genes involved in HL in Jewish Israeli samples, and we use the empirical data to develop a genetic testing algorithm for use in the Israeli population. We have updated the number of patients screened for connexin 26 mutations since this data were published in 2000 (7). We also report a mutation in the harmonin gene in Usher syndrome (USH), not previously detected in the Jewish population in Israel. Although the particular list of genes may be different in other populations, the general scheme of the algorithm is relevant to other populations as well.

SHL includes nearly 400 forms of deafness combined with other clinical findings (6); Hereditary Hearing Loss Homepage, available at http://webh01.ua.ac.be/hhh/ and Online Mendelian Inheritance in Man, available at http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim]. The severity of HL varies between and within syndromes, and some of the syndromes are rare. However, HL is most significant in several well-characterized syndromes. In the deaf Jewish Israeli sample, mutations were detected in two genes involved in USH. USH is defined by congenital NSHL, retinitis pigmentosa (RP), and vestibular dysfunction, and it accounts for more than 50% of the deaf-blind population (8), approaching a prevalence of 1 in 10,000 between the ages of 30 and 49 (9).

Nonsyndromic deafness is represented by extreme genetic heterogeneity, as up to 130 loci have been mapped and 45 nuclear genes have been identified to date, including 27 DFNB (autosomal recessive) genes, 22 DFNA (autosomal dominant) genes (7 genes are involved in both dominant and recessive forms), 1 X-linked gene, and 2 mitochondrial genes (http://webh01.ua.ac.be/hhh/). The most common form of NSHL is inherited in an Autosomal recessive mode, which accounts for up to 80% of cases (10). Autosomal dominant inherited NSHL is involved in 20% of cases and X-linked in 1%. Mitochondrial HL has been described in approximately 1 in 500 of NSHL in Europeans (11,12) and is higher in Spain (5,13). Autosomal recessive NSHL is mostly due to cochlear defects (sensoneural deafness) (14), and in the majority of cases, it is congenital profound, whereas autosomal dominant HL is mostly postlingual and progressive (10).

Deafness Genes in the Jewish Israeli Population

To achieve our goal in defining the number of genes associated with deafness in the Jewish Israeli population in Israel, we worked with most genetic centers in Israel. The project was approved by the National Helsinki Committee for...
Human Genetic Research of the Israel Ministry of Health in a multicenter study, including the Haim Sheba Medical Center, Rabin Medical Center, Hadassah Medical Center, Sourasky Medical Center, and the Wolfson Medical Center. Blood samples were obtained after informed consent from each individual and, in case of individuals under 18, from their parents.

Overall, 230 unrelated deaf Israeli Jews were investigated for deafness-causing genes. All subjects were tested for GJB2 mutations by sequencing the coding exon of the gene. The other genes involved in deafness in this population were screened in all subjects in whom GJB2 mutations were excluded. Some of the subjects belonged to large families with many deaf family members. Several such families were ascertained and genome scans were conducted, leading to mapping or cloning of the genes involved in deafness. Most of the resulting data were published previously and references are provided while describing the genes involved. A harmonin mutation, previously undetected in the Israel Jewish population, was identified in the course of this study (see later).

Anonymous DNA samples from hearing Jews of all ethnic groups were obtained from the Sheba Medical Center and from the Rabin Medical Center and used as controls. In the Jewish Israeli population, as in many populations in the world, the most common gene involved in HL is the GJB2 gene encoding the connexin 26 (Cx26) protein (7). We found that mutations only in GJB2 are associated with 27% of congenital HL in our Israeli sample (Table 1). Thus far, mutations in four additional genes are known to lead to NSHL in the Jewish Israeli population, among which is GJB6, encoding connexin 30 (Cx30) (15). Both the connexin encoding genes, GJB2 and GJB6, are involved in 31% of NSHL in the Jewish Israeli population studied. Two more genes, MYO3A (encoding myosin IIIA) (16) and SLC26A4 (encoding pendrin) (17), are involved in autosomal recessive deafness, and one gene, POU4F3 (18), is associated with autosomal dominant HL. In addition, one dominant gene has been mapped for otosclerosis, OTSC4 (19). However, according to our findings, the mutations in these six genes are involved in only approximately one third of the genetic deafness cases in the portion of the Israeli population studied. For recessive NSHL, a minimum estimate of eight to nine genes was calculated in the general deaf Israeli population (20), with a range of 7–22 loci within and between intraethnic and interethnic matings, respectively, indicating that in different ethnic groups, different loci may exist. We describe four recessive genes causing HL in less than half of our sample, suggesting that there is still more than half way to go to identify all the genes involved in deafness in the Jewish Israeli population.

### Autosomal Recessive Genes GJB2 and GJB6

GJB2 (NM_004004.4) was the first autosomal recessive gene found to cause NSHL, discovered in 1997. This was especially compelling because it has turned out to be the largest single contributor to prelingual NSHL. The GJB2 gene maps to chromosome 13q11-q12 and contains two exons of which only one is coding. GJB2 encodes Cx26, a gap junction protein of 226 amino acids. Cx26 belongs to a family of more than 20 members that share a common structure of four transmembrane segments. Most cell types express more than one connexin species, which may form homomeric or heteromeric connexons. In the auditory system, intercellular channels are formed predominantly by Cx26 but also by Cx30, Cx31, and Cx43 (21,22). Cx26 seems to be involved in maintaining a high-extracellular K concentration in the endolymph by facilitating the circulation of K+ ions (23,24).

GJB6 (NM_001110219.1) has five exons, of which only one is coding. The Cx30 protein of 261 amino acids, encoded by this gene, shares 76% identity with human Cx26 (25). GJB6, as GJB2, maps to 13q11-q12 and colocalizes with GJB2 in the same inner ear structures: in the supporting cells of the organ of Corti, in the stria vascularis, and in the spiral ligament (22). Connexons composed of Cx26 can bind connexons composed of Cx30 to form heterotypic gap junction channels (26).

#### Table 1. GJB2 (Cx26) and GJB6 (Cx30) mutations in the Jewish Israeli population (70 GJB2/GJB6 out of 230 NSHL probands)

<table>
<thead>
<tr>
<th>Mutations</th>
<th>Number of individuals</th>
<th>Ethnic group</th>
<th>Frequency among GJB2/GJB6 deafness (%)</th>
<th>Frequency among NSHL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Homozygotes for GJB2 mutations</strong></td>
<td>16</td>
<td>All</td>
<td>22.0</td>
<td>7.0</td>
</tr>
<tr>
<td>c.35delG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.167delT</td>
<td>21</td>
<td>Ashkenazi</td>
<td>30.0</td>
<td>9.1</td>
</tr>
<tr>
<td>c.51del12insA</td>
<td>3</td>
<td>Buchari</td>
<td>4.3</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>Compound heterozygotes for GJB2 mutations</strong></td>
<td>14</td>
<td>Ashkenazi, Ashkenazi-other, Syrian</td>
<td>20.0</td>
<td>6.1</td>
</tr>
<tr>
<td>c.35delG/c.167delT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.35delG/p.L90P</td>
<td>3</td>
<td>Iraqi-other</td>
<td>4.3</td>
<td>1.3</td>
</tr>
<tr>
<td>c.51del12insA/p.W24X</td>
<td>1</td>
<td>Iraqi</td>
<td>1.4</td>
<td>0.5</td>
</tr>
<tr>
<td>c.35delG/p.R32C</td>
<td>1</td>
<td>Ashkenazi</td>
<td>1.4</td>
<td>0.5</td>
</tr>
<tr>
<td>p.V37I/c.35delG</td>
<td>1</td>
<td>Ashkenazi</td>
<td>1.4</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Total deafness due to GJB2/GJB6 mutations</strong></td>
<td><strong>61</strong></td>
<td></td>
<td><strong>87.1</strong></td>
<td><strong>26.8</strong></td>
</tr>
<tr>
<td><strong>Homozygotes for GJB6 mutations</strong></td>
<td>1</td>
<td>Ashkenazi</td>
<td>1.4</td>
<td>0.5</td>
</tr>
<tr>
<td>del(GJB6-D13S1830)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Double heterozygotes: GJB2/GJB6</strong></td>
<td>3</td>
<td>Ashkenazi</td>
<td>4.3</td>
<td>1.3</td>
</tr>
<tr>
<td>del(GJB6-D13S1830)/c.35delG</td>
<td>5</td>
<td>Ashkenazi</td>
<td>7.1</td>
<td>2.2</td>
</tr>
<tr>
<td><strong>Total deafness due to GJB2/GJB6 mutations</strong></td>
<td><strong>70</strong></td>
<td></td>
<td><strong>99.9</strong></td>
<td><strong>30.8</strong></td>
</tr>
</tbody>
</table>
More than 100 mutations in GJB2 (the Connexin-Deafness
Homepage, http://davinci.crg.es/deafness/) are responsible for
up to 50% of severe to profound prelingual recessive deafness
in several worldwide populations (27,28). In Israel, in 2000,
GJB2 was reported to be involved in 38.7% of the general deaf
Israel population (7) and for 70.4% of the deaf Ashkenazi
Jews (29). In 2001, Lerer et al. (29) identified a GJB6 deletion in
the Ashkenazi Jewish population, found on one allele in
conjunction with a GJB2 mutation. The same GJB6
deletion of 342 kb was reported in Spain (31). The deletion did not
directly affect the coding region of GJB2, but truncated the
adjacent GJB6 gene, which encodes Cx30 (30–32), and it has been
shown in skin that this deletion abolishes GJB2 expression,
probably by deleting a regulatory element (33). The GJB6
deletion was found to accompany in trans, the only GJB2
mutant allele in heterozygous affected subjects (double
heterozygosity), and it was also found in homozygosity in
several cases worldwide, including in 1 individual in Israel
(15,31,32). Double heterozygotes for GJB2 and GJB6
mutations manifest the same phenotypes as homozygotes for GJB2
as well as homozygotes for GJB6 (15,30,31). This deletion,
named del(GJB6-D13S1830), was the accompanying mutation in
50% of the heterozygotes with only one GJB2 mutant
allele in different world populations (31) and in 36% (8 of 22)
of the Jewish Cx26 heterozygotes in our sample.

In our study, out of 230 Israeli probands screened for
mutations in GJB2 and GJB6, 61 (27%) were homozygotes or
compound heterozygotes for 8 mutations in GJB2 and 22 were
heterozygotes. Eight of 22 GJB2 heterozygotes (36%) were
double heterozygotes GJB2/GJB6, and one was homozygous for
the del(GJB6-D13S1830) mutation. Combining the GJB2 and
GJB6 mutations, the estimated prevalence of NSHL in-
volving connexins is 31%, lower than the 38% reported
previously (7), but still remaining the main known cause for
congenital deafness among the Jews in Israel. Table 1
summarizes the GJB2 and GJB6 mutations detected in the Jewish
Israeli sample.

The most common mutations in the Israeli population are
the biallelic truncating mutations, c.35delG and c.167delT,
and therefore, the degree of HL of most individuals with
connexin-related HL ranges from severe to profound. All the
deafness in which del(GJB6-D13S1830) is involved is severe
to profound as well. The few cases in which the nontruncating
mutations p.V37I and p.L90P are associated, mild-to-
moderate HL is observed (Table 2). All our findings are
compatible with those of other populations, as was presented
by a worldwide multicenter study comprising 1531 genetically
and audiometrically documented individuals with connexin
autosomal recessive HL (34).

Distinct mutations were associated with certain ethnic
groups and were not detected in Jewish deaf individuals
originating elsewhere, i.e. c.167delT was found mostly among
Ashkenazi Jews and in several cases of deaf individuals
originating in Syria; the del(GJB6-D13S1830) mutation was
detected only among Ashkenazi Jews; the c.51del12insA
frame shift mutation was found to be unique to Bukharan deaf
Jews; whereas the p.L90P missense mutation was identified
only in deaf individuals originating in Iraq. In many genetic
clinical laboratories in Israel, only the c.35delG and the
c.167delT mutations are screened by restriction enzyme
assays. Based on our findings, it is clear that at least in some
ethnic groups other mutations exist. Because the GJB2 gene
has only one coding exon and the other mutations detected in
Israel are also found frequently outside of the Jewish commu-
nity, the complete coding region of the GJB2 gene should be
sequenced as a routine, and considering ethnicity of the deaf
individual, additional tests for the splice site mutation and the
GJB6 deletion should be performed.

### Autosomal Recessive Gene MYO3A

Myosin IIIA (MYO3A; NM_017433.4) maps to chromosome
10p11.1 and contains 35 exons (http://genome.ucsc.edu).
The 1616 amino acid protein encoded by this gene belongs to
the myosin superfamily. Myosins are actin-dependent motor
proteins and are categorized into conventional myosins
(class II) and unconventional myosins (classes I and III
through XV) based on their variable C-terminal cargo-
binding domains. Class III myosins, expressed in photore-
ceptors, are hybrid motor-signaling molecules, with an
N-terminal kinase domain, highly conserved head and neck
domains, and a class III-specific tail domain. Expression of
this gene is highly restricted, with the strongest expression
in retina and cochlea (16).

---

**Table 2. Severity of the GJB2 and GJB6 mutations in a Jewish Israeli sample**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Profound</td>
<td>11</td>
<td>10</td>
<td>9</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Severe</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>5</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>13</td>
<td>17</td>
<td>13</td>
<td>3</td>
<td>5</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Subjects are classified based on audiogram data on the better performing ear.

*Profound HL, >95dB; severe HL, 71–95 dB; moderate HL, 41–70 dB; Mild HL 21–40 dB.
*GJB6-D13S1830.
Three different autosomal recessive, loss-of-function mutations in MYO3A are involved in progressive NSHL in an extended Israeli family, originating in Mosul, Iraq (16). The HL begins in the second decade, first affects the high frequencies, and by age 50 is severe in high and middle frequencies and moderate at low frequencies. The mutations detected include a nonsense mutation c.3126T>G, p.Y1042X causing protein truncation at the junction of the head and neck domains of the myosin IIIA protein; a mutation in the splice acceptor of intron 17, 1777(-12)G->A, leading to deletion of exon 18 and protein truncation at codon 668 in the myosin head domain; and a mutation in the splice acceptor of intron 8, 732(-2)A->G, resulting in an unstable message, as revealed by the absence of message from this allele in carriers of the mutation. Of 18 affected individuals in this family, 7 are homozygous and 11 are compound heterozygous for pairs of mutant alleles. A genotype-phenotype correlation was observed among the deaf members of the family. Between the ages of 25 and 50, hearing across all frequencies was significantly poorer, and the rate of progress was higher among the individuals homozygous for the nonsense mutation comparing to the compound heterozygotes for the nonsense mutation and either of the splice mutations.

Among 172 Iraqi Jewish hearing controls, four (2.3%) carried the nonsense mutation; none carried either splice mutation. None of the three mutations were observed among 96 Ashkenazi Jewish hearing controls (Table S1, Supplemental Digital Content 1, http://links.lww.com/PDR/A43).

As for the phenotypic-clinical aspect, the MYO3A gene is unique in that 1) mutations in this gene are involved in an uncharacteristic autosomal recessive HL, which unlike the other recessive deafness is late onset and progressive, and 2) three different MYO3A mutations underlies deafness in the same family. The existence of multiple MYO3A mutations in the same kindred also suggests that other mutations in this gene may be involved in recessive late onset HL.

**Autosomal Recessive Gene SLC26A4**

More than 100 mutations in the PDS (SLC26A4) gene are involved in both Pendred syndrome (PS) and NSHL DFNB4 associated with temporal bone abnormalities (35). The SLC26A4 gene (NM_000441.1), located on the long arm of chromosome 7, contains 1 noncoding and 20 coding exons and encodes pendrin, a protein of 780 amino acids, expressed in various tissues, including the inner ear, thyroid, and kidney.

The HL caused by mutations in SLC26A4 is mostly congenital, nonsyndromic high frequency, but sometimes postlingual progressive SNHL and associated with malformations of the temporal bone. The temporal bone abnormalities vary, ranging from isolated enlarged vestibular aqueduct (EVA) to Mondini dysplasia, an abnormality in which the normal cochlear spiral of 2.5 turns is replaced by a hypoplastic coil of 1.5 turns. Albert et al. (35) estimated that SLC26A4 mutations are involved in 4% of NSHL, which emphasizes the importance of the molecular confirmation of the PDS gene in the diagnosis of deafness and particularly when temporal bone abnormality conditions are involved.

The c.1458_1459insT mutation of the SLC26A4 gene was detected in a Jewish Iranian proband with NSHL and EVA after excluding mutations in Cx26 (17). The deaf individual had progressive postlingual HL that began at age 6 and progressed to profound deafness. In his mid twenties, he underwent cochlear implantation. In his presurgery CT, EVA was observed and therefore the SLC26A4 gene was sequenced. The c.1458_1459insT mutation was detected on both alleles. The mutation causes a frameshift at position 487 in exon 13 (of 21), leading to a stop codon at position 526 in exon 14 of the SLC26A4 gene, p.Ile487TyrfsX39.

An additional 203 deaf probands, in which mutations in the connexins were excluded, were screened for the c.1458_1459insT mutation (17). Three individuals with Mondini dysplasia were included in this population. All 203 probands were wild type for this nucleotide. In total, the probability of the c.1458_1459insT mutation of the PDS gene, among the Jewish deaf population in Israel, is 0.5% (1 of 204). Normal hearing controls (310) were screened, including 21 of Iranian ethnic origin, and all 310 were found to be WT, i.e. no carriers of the mutation were detected (Table S1, Supplemental Digital Content 1, http://links.lww.com/PDR/A43).

**USH Gene PCDH15**

Three clinical subtypes, USH1–3, are described based on the characteristics of deafness, vestibular involvement, and RP. Defects in protocadherin 15 (PCDH15) cause USH1F (36,37). USH1 is the most common and most severe and characterized by congenital profound deafness, onset of RP in the beginning of the second decade of life, and constant vestibular dysfunction.

PCDH15 (NM_033056.3) is located on chromosome 10q11.2–q21. The PCDH15 gene contains 33 exons, one of which is noncoding, and it is predicted to encode a protein of 1955 amino acids. Mice carrying a mutation in Pcdh15 show disorganization in the placement of the stereocilia. It was suggested that PCDH15 plays a role in regulation of planar polarity in the sensory neuroepithelium of the inner ear. Members of the cadherin superfamily are also required in the eye and inner ear for maintenance of normal function (38). Recently, PCDH15 has been shown to be a part of the tip link complex, together with cadherin 23 (39).

The R245X mutation is caused by a C to T transition at position 733 in exon 8 of the PCDH15 gene, and it leads to the substitution of an arginine by a stop codon in the extracellular, second (of 11) cadherin domain. The R245X mutation accounts for more than half (58.3%) of USH in the Ashkenazi Jewish population. This mutation was detected only among Ashkenazi Jews and was not detected in other Jewish ethnic groups (40). In our study, Ashkenazi Jewish individuals (n = 59) diagnosed with NSHL were screened for the R245X mutation (41). Twenty of the probands were younger than 10 y, and 39 were older than 10 y. This age distinction was chosen because RP is typically diagnosed after the age of 10 (42). In the first group of children under 10, 2 of 20 (10%) were homozygous for R245X. In the older group, no homozy-
gotes were detected; but 1 of 39 (2.6%) was heterozygous for the R245X mutation.

To determine the carrier rate, 505 DNA samples of hearing Ashkenazi Jews were screened for the R245X mutation. Five out of 505 (0.99%) were heterozygous for the mutation (Table S1, Supplemental Digital Content 1, http://links.lww.com/PDR/A43). The R245X mutation was not detected among 293 non-Ashkenazi Jews screened elsewhere (40), and the mutation is assumed to be a founder effect in the Ashkenazi ethnic group.

These findings led to the inevitable consequence that Ashkenazi children diagnosed with NSHL should be evaluated for the R245X mutation to determine whether they will develop RP before clinical signs of this retinal defect, detectable by funduscopy and ERG. Habilitation can then begin before loss of vision.

**USH Gene USH1C (Harmonin)**

Mutations in harmonin are associated with USH1C, a subtype of USH1, and are characterized by congenital deafness, RP, and vestibular dysfunction. The **USH1C** gene (NM_153676.2) maps to chromosome 11p15.1 and contains 27 exons, encoding a protein of 899 amino acids. Mutations in USH1C, as well as mutations in myosin VIIa (MYO7A), CDH23, PCDH15, or sans lead to USH1 in humans and hair bundle disorganization in mice. It was suggested that harmonin anchors the tip link upper end (likely to be made of cadherin 23) to the stereocilia actin core, hence, playing a key role in hair bundle cohesion and proper orientation of the stereocilia; it is also involved in stereociliary elongation (43).

The c.238–239InsC mutation causes a frameshift at position 78 in exon 3 (of 27), leading to a stop codon at position 148 in exon 5 of the **USH1C** gene, p.Tyr78TyrfsX70 (44). Previously identified only outside of Israel (44,45), this mutation was recently detected in Israel in two brothers with congenital deafness, born to unrelated Ashkenazi-Jewish parents. We describe this data here for the first time. The two children, 5- and 1-y-old, were misdiagnosed as having NSHL. Homozygosity mapping was conducted using the GeneChip Human Mapping 250 K Nsp Array of Affymetrix, revealing a 13.63-Mb homozygous region on chromosome 11p15.4-p15.1. Homozygosity was further confirmed by five microsatellite markers, which spanned the region (including the commercially available D11S4149, D11S4116, and D11S902; Orly Elpeleg, personal communication, Hadassah Hebrew University Medical Center, Jerusalem, Israel, 2008). Of the 174 genes in this region, the harmonin gene at chromosome 11p15.1-p14, associated with USH1C and with nonsyndromic recessive deafness (DFNB18), was a good candidate. The mutation c.238-239InsC was detected by sequencing this gene. Funduscopy confirmed onset of RP in the older brother.

Exon 3 of the harmonin gene was sequenced in addition to 20 USH unrelated controls and none of them harbored the mutation. Normal hearing controls were screened (384), including 271 of Ashkenazi origin and 113 of non-Ashkenazi ethnic groups. No carriers of the mutation were detected (Table S1, Supplemental Digital Content 1, http://links.lww.com/PDR/A43).

Because harmonin, as **PCDH15**, is a subtype of USH1, in which the onset of RP is in the beginning of the second decade of life, children are often misdiagnosed as having NSHL instead of USH. Therefore, children with no family history of deafness and with no GJB2/ GJB6 mutations should be evaluated for the c.238-239InsC mutation.

**Autosomal Dominant Gene POU4F3**

**POU4F3** is a member of the POU family of transcription factors, with expression mostly restricted to hair cells of the inner ear (46,47), and it is essential for inner ear hair cell maintenance. The 2-exon **POU4F3** gene (NM_002700.1) maps to chromosome 5q31 and encodes a protein of 338 amino acids. In hearing impaired members of one large Israeli Jewish family originating in Lybia, an 8 bp deletion was identified, starting at nucleotide 884 (884del8) of exon 2 of the **POU4F3** gene (18). The predicted result of this deletion is a frameshift beginning at the second nucleotide of codon 295 and a premature translation stop at position 302, p.Ile295ThrfsX7. The 884del8 mutation in the **POU4F3** gene is associated with late onset, progressive, NSHL. This deletion leads to a frameshift, predicted to cause a stop codon to be formed prematurely in the first helix of the POU-homodomain. Mutant **POU4F3** loses most of its transcriptional activity and most of its ability to bind to DNA. Moreover, although wild-type **POU4F3** is found exclusively in the nucleus, it was demonstrated that the mutant protein is localized both to the nucleus and the cytoplasm, where transcriptional activity cannot be carried out (48).

Affected members suffer from progressive high-tone, autosomal dominant SNHL, with onset between ages 18 and 30 y. The hearing impairment becomes more severe with time, eventually causing significant HL across the spectrum at all frequencies (49). Two novel missense mutations were recently discovered, in the Dutch population, with a similar phenotype to the Israeli family (50).

Twenty-seven autosomal dominant deaf screened were negative for the mutation, resulting in the prevalence of 3.5% (1 of 28) of the mutation in the **POU4F3** gene among autosomal dominant HL in our study. To determine the carrier rate, 114 unrelated individuals of various North African and Middle Eastern Jewish ancestries were tested for the mutation. None of the 228 control chromosomes tested carried the 8 bp deletion in **POU4F3** found in the Jewish Lybian family.

**A Mapped Locus for Otosclerosis OTSC4**

Otosclerosis is a common bone disorder with a prevalence of 0.2 to 1% among adults, leading to a progressive hearing impairment that begins as a conductive HL, and might develop into a mixed to SNHL, with an autosomal dominant mode of inheritance with reduced penetrance. The age of onset for otosclerosis is usually 20–40 y and in most cases both ears are involved, but HL is often asymmetric (51). A definitive diagnosis of otosclerosis can be made only by surgery, but existence of family history of the disease and some other clinical characterizations are considered sufficient to diagnose otosclerosis in a family where only some members were surgically confirmed (52–54). Both environmental and genetic factors have been implicated in otosclerosis. A 2:1 female-to-male predominance suggests hormonal involvement as well (55).
We mapped a new otosclerosis locus, OTSC4, to chromosome 16q21-23.2 in a Yemenite Israeli family with otosclerosis (19). The hearing impairment in the family ranged from conductive to mixed-to SNHL, from unilateral to bilateral HL, with variable severity, age of onset, and progression. The considerable inter-subject and interaural variability within the same family might be because of the different stages of the activity of the otosclerotic lesion, which are thought to be directly correlated to the type and severity of HL and audiogram configuration.

Implications for Patients With HL

Except for the GJB2/GJB6 genes involved in one third of the nonsyndromic deaf population of our study, all the other deafness genes are of low prevalence, frequently detected in one family only (Table S1, Supplemental Digital Content 1, http://links.lww.com/PDR/A43). There is no doubt that GJB2 should be sequenced first in each hearing impaired individual, followed by screening for the large deletion truncating GJB6 in all the Ashkenazi deaf in which GJB2 was ruled out. Today, it is tedious and not cost-effective to screen the known genes in Israel routinely after mutations in GJB2/GJB6 are ruled out. Therefore, we suggest a diagnostic algorithm (Fig. 1) for Jewish individuals presenting with HL, depending on the mode of inheritance, ethnic origin, and clinical/audiological manifestation, and taking into account the most cost-efficient method to address the molecular diagnoses available today. Furthermore, other genes that have been implicated in HL in other parts of the world but not yet found in Israel should be considered when the relevant phenotype is discovered. For example, inherited in a dominant form for nonsyndromic deafness, WFS1 mutations are associated with low frequency HL (56). Patients with dominant COCH mutations have a characteristic vestibular dysfunction that is similar to Meniere’s disease and is associated with HL that begins in the third decade, with high frequencies affected first (57). If aminoglycosidase damage is suspected, the mitochondrial 12S rRNA mutation should be examined, particularly if the HL appears to follow a maternal form of inheritance (58). TECTA mutations may be responsible when prelingual, nonprogressive, midfrequency hearing impairment is observed (59). Recessive auditory neuropathy, characterized by the absence of detectable responses to auditory evoked potentials (AEP) and the presence of bilateral TEOAEs, may be associated with mutations in the OTOF gene (60,61). The identification of genes in the world is a dynamic process, with new genes and mutations being found monthly. Therefore, the literature and the Hereditary Hearing Loss Homepage should be scrutinized routinely to determine whether there are additional genes that should be examined in a patient presenting with suspected genetic hearing impairment. In the future, DNA arrays may be designed that will make screening multiple genes/variants more cost efficient. Furthermore, as we gain knowledge of a complete repertoire of genes involved in hearing, and technology advances, the approach to future treatment and intervention will change accordingly. In particular, there is promise for gene and cell therapy (62,63) with this increased knowledge and advanced tools, and the future holds great promise for the hearing impaired population.

Acknowledgments. We thank all the families who contributed to the studies described in this review, without whom this work could not have taken place. Their participation in the study enabled many more families to learn about their genetic basis of HL. We also thank our collaborators over the years that have been involved in patient ascertainment and gene identification and contributed an essential component to the success of this work. We especially thank Prof. Moshe Frydman, a devoted clinician and researcher, whose guidance and dedication has carried us throughout this project.

REFERENCES

6. BROWNSTEIN AND AVRAHAM


Copyright © 2019 Pediatric Research Institute Inc.